Vesting of awards under Long Term Incentive Plan

Hutchmed (China) Limited

11 March 2026

 

Vesting of awards under the Long Term Incentive Plan

Hong Kong, Shanghai & Florham Park, NJ - Wednesday, March 11, 2026: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) announces that following the announcement of the 2025 annual results of HUTCHMED on March 5, 2026, the following awards granted under the Long Term Incentive Plan ("LTIP") on June 5, 2023 to Dr Weiguo Su and Mr Johnny Cheng were vested on March 10, 2026:-

Award Holders	Number of ordinary shares
Person Discharging Managerial Responsibilities
Dr Weiguo Su (Executive Director, Chief Executive Officer and Chief Scientific Officer)	524,079
Mr Johnny Cheng (Executive Director, Acting Chief Executive Officer and Chief Financial Officer)	202,238
Total	726,317

The notifications set out below are provided in accordance with the requirements of the UK Market Abuse Regulation.

(a)  Dr Weiguo Su

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Dr Weiguo Su
2	Reason for the notification
a)	Position/status	Executive Director, Chief Executive Officer and Chief Scientific Officer
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	HUTCHMED (China) Limited
b)	LEI	2138006X34YDQ6OBYE79
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of US$0.10 Ordinary Share with DI ISIN: KYG4672N1016
b)	Nature of the transaction	Vesting of awards granted on June 5, 2023 under HUTCHMED's LTIP
c)	Price(s) and volume(s)	Price(s) Volume(s) Nil 524,079 ordinary shares
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	2026-03-10
f)	Place of the transaction	Outside a trading venue

(b)  Mr Johnny Cheng

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Mr Johnny Cheng
2	Reason for the notification
a)	Position/status	Executive Director, Acting Chief Executive Officer and Chief Financial Officer
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	HUTCHMED (China) Limited
b)	LEI	2138006X34YDQ6OBYE79
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of US$0.10 Ordinary Share with DI ISIN: KYG4672N1016
b)	Nature of the transaction	Vesting of awards granted on June 5, 2023 under HUTCHMED's LTIP
c)	Price(s) and volume(s)	Price(s) Volume(s) Nil 202,238 ordinary shares
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	2026-03-10
f)	Place of the transaction	Outside a trading venue

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.

CONTACTS

Investor Enquiries	[phone] / [e-mail]
Media Enquiries
FTI Consulting -	[phone] / [e-mail]
Ben Atwell / Tim Stamper	[phone] (Mobile) / [phone] (Mobile)
Brunswick - Zhou Yi	[phone] (Mobile) / [e-mail]
Panmure Liberum	Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden	[phone]
Cavendish	Joint Broker
Geoff Nash / Nigel Birks	[phone]
Deutsche Numis	Joint Broker
Freddie Barnfield / Jeffrey Wong / Duncan Monteith	[phone]

 

END